BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288


View Clinical Trials from BioPharm Insight

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

 Key Statistics

Email: n/a
Ownership: Public

Web Site: AmpliPhi Biosciences Corporation
Symbol: APHB


Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.

 Company News
AmpliPhi Biosciences Corporation (APHB) Provides Corporate Update And Reports First Quarter 2015 Financial Results 5/19/2015 12:48:32 PM
AmpliPhi Biosciences Corporation (APHB) Provides Corporate Update And Reports First Quarter 2015 Financial Results 5/19/2015 10:04:09 AM
AmpliPhi Biosciences Corporation (APHB) Announces M. Scott Salka As New CEO 5/1/2015 10:21:36 AM
AmpliPhi Biosciences Corporation (APHB) Granted European Patent For Bacteriophage Therapy To Fight Biofilm-related Bacterial Infections 3/31/2015 8:52:38 AM
AmpliPhi Biosciences Corporation (APHB) Announces $13 Million Financing 3/11/2015 9:02:34 AM
AmpliPhi Biosciences Corporation (APHB) Provides Shareholder Update 1/6/2015 8:35:53 AM
AmpliPhi Biosciences Corporation (APHB) To Host Shareholder Update Conference Call 12/31/2014 8:05:43 AM
AmpliPhi Biosciences Corporation (APHB) Announces Departure Of CEO 9/19/2014 6:20:28 AM
AmpliPhi Biosciences Corporation (APHB) To Present At Rodman & Renshaw 16th Annual Global Investment Conference 9/4/2014 12:35:14 PM
AmpliPhi Biosciences Corporation (APHB) Announces Appointment of New Board Member 5/22/2014 7:38:18 AM